Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema

Retina

Volumn 33, Issue 8, 2013, Pages 1623-1629

  Solaiman, Kamal A M ^a   Diab, Mohammad M ^b,d   Dabour, Sherif A ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d Maghraby Eye Hospital   (United States)

Author keywords

diffuse diabetic macular edema; intravitreal bevacizumab; macular grid photocoagulation

Indexed keywords

BEVACIZUMAB; MOXIFLOXACIN;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIFFUSE DIABETIC MACULAR EDEMA; DISEASE FREE INTERVAL; DRUG EFFICACY; EYE; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; INJECTION; LASER COAGULATION; MACULAR GRID PHOTOCOAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; SUBCONJUNCTIVAL HEMORRHAGE; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84883740325     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318285c99d     Document Type: Article

References (31)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
2. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474.
3. Klein R, Moss SE, Klein BE, et al. The Wisconsin Epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501-1510.
4. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653-2664.
5. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-232.
6. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008;28:420-426.
7. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse macular edema. Long term visual results. Ophthalmology 1991;98:1594-1602.
8. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986; 93:938-950.
9. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina 1985;5:65-72.
10. Bandello F, Lanzetta P, Menchini U. When and how to do a grid laser for diabetic macular edema. Doc Ophthalmol 1999;97:415-419.
11. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 2006;26:5-13.
12. Mochizuki Y, Hata Y, Enaida H, et al. Evaluating adjunctive surgical procedures during vitrectomy for diabetic macular edema. Retina 2006;26:143-148.
13. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
14. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112: 806-816.
15. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
16. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology 2007;114:743-750.
17. Soheilian M, Ramezani A, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-1195.
18. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular grid photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638-1645.
19. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
20. Lee CM, Olk J, Akduman L. Combined macular grid and combined panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy. Ophthalmic Surg Lasers 2000;31:292-300.
21. Bakri SJ, Snyder MR, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
22. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219.
23. Wu L, Arevalo JF, Berrocal MA, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions. Results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 2009;29:1396-1403.
24. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008;28:1314-1318.
25. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010;117:2146-2151.
26. Wallow IH. Repair of the pigment epithelial barrier following photocoagulation. Arch Ophthalmol 1984;102:126-135.
27. Forte R, Cennamo G, Vecchio CE, et al. Bevacizumab in macular edema. Functional and anatomic changes in a prospective case series. Retina 2009;29:941-948.
28. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
29. Michaelides M, Kaines A, Hamilton RD, et al. A prospective radomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study). 12-month data: Reort 2. Ophthalmology 2010;117:1078-1086.
30. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioassays 2004;26:943-954.
31. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 2006;26: 12439-12446.